Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on GRAFENIA PLC. We currently have 35 research reports from 3 professional analysts.
|24Feb17 07:00||RNS||Director/PDMR Sharedealing|
|24Feb17 07:00||RNS||Employee Share Scheme|
|21Feb17 07:00||RNS||Trading update|
|08Dec16 10:45||RNS||Holding(s) in Company|
|16Nov16 15:08||RNS||Director/PDMR Shareholding|
|09Nov16 12:24||RNS||Directors' Dealings|
Frequency of research reports
Research reports on
N+1 Singer - Grafenia - Weak print volumes
21 Feb 17
Trading conditions are still challenging and management remains cautious on the outlook. The new initiatives continue to progress, however, weak print volumes in January and early February has led us to reduce our LBT forecast from £0.3m to £0.6m. We continue to forecast net cash on the balance sheet (c.£0.6m by the year end). A further update is expected in April.
Small Cap Breakfast
16 Jan 17
Global Energy Development (GED.L) — To be renamed Nautilus Marine Services. Schedule 1 from developer and seller of hydrocarbons and related products. Reverse takeover. Raising $10.5m via a convertible. Expected 9 Feb. Eco (Atlantic) Oil & Gas—TSX-V listed oil and gas exploration has announced its intention to float on AIM. Assets in Guyana and Namibia. Proposed £2m-£3m fundraise. Diversified Gas & Oil—According to LSE website first day of trading on AIM now expected for 30 January.
N+1 Singer - Morning Song 08-11-2016
08 Nov 16
BBA Aviation (BBA LN) Trading in line; Positive bolt-on | EMIS Group (EMIS LN) Shares oversold, fundamentals intact | First Derivatives (FDP LN) Moving into retail analytics | Grafenia (GRA LN) Conditions remain tough | PCI-PAL (PCIP LN) Special dividend confirmed | Trifast (TRI LN) Another strong performance; forecasts upgraded
N+1 Singer - Morning Song 14-10-2016
14 Oct 16
Applied Graphene Materials (AGM LN) First production order | Carclo (CAR LN) Complementary acquisition; trading in line | Grafenia (GRA LN) Conditions challenging; trading improving | Oxford BioMedica (OXB LN) Forecasts updated, upgrade to Hold | Thin Film Electronics ASA (THIN NO) Acquisition of high volume manufacturing capability is milestone event
N+1 Singer - Morning Song 21-03-2017
21 Mar 17
accesso Technology (ACSO LN) Full year results in line, but key trading months still ahead | Augean (AUG LN) Double digit growth in ’16, good start to ‘17 | Earthport (EPO LN) Interims show continued top line strength | Goals Soccer Centres (GOAL LN) Good momentum under new team. It’s now all about delivery | IQE (IQE LN) FY’16 results prompt further upgrades | Microsaic Systems (MSYS LN) Challenges in 2016, strategy remains in place | mporium Group (MPM LN) Funds raised to help execute strategy | RhythmOne (RTHM LN) Dawn of the independents | ScS Group (SCS LN) Strong progress on key growth initiatives albeit comps now toughen | Sinclair Pharma (SPH LN) FY results: EBITDA ahead, Instalift™ gaining pace | Vectura Group (VEC LN) FY (9-month) results
N+1 Singer - Augean - Double digit growth in ’16, good start to ‘17
21 Mar 17
Augean reported another year of double digit growth for 2016, with profits in line with our forecasts. Sales grew by 21% excluding landfill tax, while adjusted PBT grew by 18% to £7.1m before amortisation of acquired intangibles. DPS was increased by 54% to 1.0p, 25% ahead of our estimate. The business units made further strategic progress, with revenues from their top 20 customers increasing from 42% to 43% of the total, of which 88% was under contract or a framework agreement, increasing forward visibility. There has been an encouraging start to 2017 and management is confident of delivering another year of profits growth. The shares trade on undemanding single digit multiples, offering good value.
N+1 Singer - Morning Song 22-03-2017
22 Mar 17
Carador Income Fund (CIFU LN) Premium rating restored, high levels of refinancing activity | Cello Group (CLL LN) Outlook getting brighter – watch Pulsar | Eckoh (ECK LN) Largest ever US secure payments win | eg solutions (EGS LN) Full year results in line | Futura Medical (FUM LN) Licensing deal for CSD500 in Portugal | Verona Pharma (VRP LN) Global agreement with QuintilesIMS to support development of RPL554 | Xaar (XAR LN) 2016 results slightly ahead, reduced visibility in 2017